|
Mr. Klein is a founding member of Red Abbey. Having spent 15 years as an active life sciences investor and industry analyst, Mr. Klein has worked with both Mr. Bonsal and Mr. Zuga in a variety of capacities. Mr. Klein is currently Managing Director of Gauss Capital Advisors, LLC, a financial advisory and investment consulting firm which he founded in March 1998. Gauss Capital’s objective is to help life sciences investors and companies find compelling investment opportunities in the tails of the normal distribution, by performing due diligence and investment advisory services. Gauss Capital’s clients have included a hedge fund, a major mutual fund, an investment banking firm and several biopharmaceutical companies. From September 2001 to September 2002, Mr. Klein served as a Venture Partner of MPM Capital, L.P., one of the largest healthcare venture capital firms in the world. From June 1999 to September 2000, Mr. Klein served as Vice President, Strategy for Medical Manager Corporation, a physician office management information systems vendor. From June 1998 to June 1999, Mr. Klein served as the Health Care Investment Analyst for The Kaufmann Fund, Inc., an open-ended mutual fund. From December 1995 to March 1998, Mr. Klein was founding Portfolio Manager and Chairman of the Investment Advisory Committee of the T. Rowe Price Health Sciences Fund, Inc., an open-ended mutual fund focusing on life sciences. Under his management, the Health Sciences Fund was the top performing health care fund in 1996, and third best performing of 18 funds monitored by Lipper Analytical from inception to December 31, 1997. For over nine years from 1989 to March 1998, Mr. Klein served as Vice President and Health Care Investment Analyst for T. Rowe Price Associates, Inc., an investment management firm. Mr. Klein holds an MBA from the Stanford Graduate School of Business and a BA summa cum laude in Economics from Yale University, where he was elected to Phi Beta Kappa. Mr. Klein is a Director of four publicly held biotechnology companies: BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), Isis Pharmaceuticals Inc. (NASDAQ: ISIS), OSI Pharmaceuticals, Inc. (NASDAQ: OSIP) and Savient Pharmaceuticals, Inc. (NASDAQ: SVNT). | 